carnitine has been researched along with fenofibrate in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 3 (30.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Bezard, J; Cao Danh, H; Clouet, P; Henninger, C; Pascal, M | 1 |
Beauseigneur, F; Clouet, P; Demarquoy, J; Gresti, J; Tsoko, M | 1 |
Asai, T; Matsui, H; Murakami, H; Murakami, R; Murohara, T; Numaguchi, Y; Okumura, K; Takahashi, R | 1 |
Fujita, M; Fukushi, A; Funabashi, M; Maeda, T; Motojima, K; Tamai, I; Wakasawa, T | 1 |
Gonzalez, FJ; Höfer, CC; Idle, JR; Krausz, KW; Li, F; Patterson, AD; Perlík, F; Slanar, O | 1 |
Hofbauer, R; Kienesberger, K; Pordes, AG; Völk, TG | 1 |
Holeček, M; Vodeničarovová, M | 1 |
10 other study(ies) available for carnitine and fenofibrate
Article | Year |
---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Effects of fenofibrate treatment on fatty acid oxidation in liver mitochondria of obese Zucker rats.
Topics: Animals; Carnitine; Carnitine O-Acetyltransferase; Fatty Acids; Fenofibrate; Hypolipidemic Agents; Male; Malonyl Coenzyme A; Mitochondria, Liver; Oxidation-Reduction; Palmitoyl Coenzyme A; Propionates; Rats; Rats, Zucker | 1987 |
Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver.
Topics: Animals; Carnitine; Cholesterol; Fenofibrate; Hypolipidemic Agents; Ketone Bodies; Liver; Male; Methylhydrazines; Muscle, Skeletal; Myocardium; Phospholipids; Rats; Rats, Wistar; Triglycerides | 1998 |
Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathy, Hypertrophic; Carnitine; Diglycerides; Drug Therapy, Combination; Echocardiography; Fatty Acids; Fatty Liver; Fenofibrate; Mice; Mice, Inbred C3H; Mice, Mutant Strains; Models, Animal; Myocardium; Peroxisome Proliferator-Activated Receptors; PPAR alpha; Protein Kinase C; Random Allocation; Treatment Outcome; Triglycerides | 2006 |
Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha.
Topics: Animals; Blotting, Northern; Carnitine; Cell Line, Tumor; Cell Separation; Cells, Cultured; Electrophoretic Mobility Shift Assay; Fenofibrate; Genes, Reporter; Hepatocytes; Hypolipidemic Agents; Luciferases; Male; Organic Cation Transport Proteins; Plasmids; PPAR alpha; Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Solute Carrier Family 22 Member 5; Transfection | 2008 |
Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.
Topics: Adult; Algorithms; Analysis of Variance; Animals; Artificial Intelligence; Biomarkers; Carnitine; Chromatography, High Pressure Liquid; Fatty Acids; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Mass Spectrometry; Metabolome; Metabolomics; Mice; Mice, Inbred C57BL; Pantothenic Acid; PPAR alpha; Urine | 2009 |
L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells.
Topics: 5' Untranslated Regions; Animals; Base Sequence; Carnitine; Carnitine O-Acetyltransferase; Cell Nucleus; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Gene Order; Hepatocytes; Mice; Molecular Sequence Data; PPAR alpha; Promoter Regions, Genetic; Protein Binding; Protein Transport; RNA, Messenger | 2014 |
Effects of low and high doses of fenofibrate on protein, amino acid, and energy metabolism in rat.
Topics: Amino Acids; Amino Acids, Branched-Chain; Animals; Carnitine; Energy Metabolism; Fenofibrate; Glycine; Hepatomegaly; Humans; Hypolipidemic Agents; Leucine; Liver; Lysine; Male; Methionine; Muscle, Skeletal; Oxidation-Reduction; Proteins; Rats; Rats, Wistar | 2020 |